Drug intelligence / Profile preview

RMX-GPC3

Development stage: Preclinical
Lead developer: Radiomedix
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous (inferred From Standard Practice For Therapeutic Radiopharmaceuticals)

Overview

RMX-GPC3 is a therapeutic radiopharmaceutical being developed as a theragnostic agent targeting glypican-3 (GPC3), an antigen highly expressed in several solid malignancies, including hepatocellular carcinoma, urological cancers, yolk sac tumors, and ovarian cancers. The drug is designed to address unmet needs in both the diagnosis and treatment of GPC3-positive neoplasms. Its mechanism involves inhibiting GPC3, which plays a role in tumor growth and proliferation. RMX-GPC3 is currently in preclinical development by RadioMedix[1][2].

Targets

GPC3 (Glypican-3)

Beyond the preview

Go deeper on RMX-GPC3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RMX-GPC3.

Explore the full profile